Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VERA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVera Therapeutics stockholders approve routine annual meeting matters, elect directors
Filed May 26, 2026 · Period ending May 21, 2026 · ~1 min read
Key Changes
-
low
Stockholders elected three Class II directors to serve three-year terms through 2029: Michael Morrisey, Patrick Enright, and James Meyers. Meyers received strongest support while Morrisey had most withheld votes at 13.8 million.
Item 5.07 verify on EDGAR → -
low
KPMG LLP ratified as independent auditor for fiscal 2026 with overwhelming support (61.8 million for vs 44,710 against).
Item 5.07 verify on EDGAR → -
low
Executive compensation approved on advisory basis with 56.6 million votes for versus 2.4 million against, indicating general shareholder support for management pay structure.
Item 5.07 verify on EDGAR →
Summary
Vera Therapeutics held its 2026 Annual Meeting on May 21, with stockholders approving all routine matters on the ballot. The company elected three Class II directors to three-year terms, ratified its auditor, and gave advisory approval to executive compensation. All votes passed with comfortable margins, suggesting no significant shareholder dissent on governance or compensation matters.
For retail investors, this filing represents standard corporate housekeeping with no material business developments. The voting results show typical patterns for uncontested director elections and routine proposals.
The most notable data point is the variation in director votes, with one nominee receiving about 13.8 million withheld votes compared to minimal opposition for others, though this still represents a clear majority approval. Watch for the company's next quarterly earnings report or clinical trial updates for material business developments. Annual meeting filings like this are procedural and don't typically move stock prices or signal operational changes.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Vera Therapeutics held its 2026 Annual Meeting, electing three Class II directors, ratifying KPMG as auditor, and approving executive compensation.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director’s death, resignation or removal.
Three Class II directors were elected at the Annual Meeting: Michael M. Morrisey, Ph.D., Patrick G. Enright, and James R. Meyers. Each will serve a three-year term until the 2029 Annual Meeting. Meyers received the strongest support with 58,946,269 votes for versus 157,112 withheld, while Morrisey had the most withheld votes at 13,814,671.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 27, 2026 · How we verify